{
    "data": [
        {
            "id": "690390d8ecb8a70001459fa1",
            "title": "Cardinal Health Rallies As Strong Start To 2026 Fuels Higher Earnings Guidance",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Cardinal Health Inc.’s </strong>(NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CAH\" target=\"_blank\">CAH</a>) stock surged on Thursday as the healthcare services company reported upbeat first-quarter 2026 earnings, with adjusted earnings of $2.55 per share, beating the <a href=\"https://www.benzinga.com/calendars/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">consensus of $2.18</a>.</p><!--/$--><!--$--><p class=\"block core-block\">Sales increased 22% year over year to $64.01 billion, surpassing the consensus estimate of $59.19 billion. Adjusted operating earnings <a href=\"https://www.benzinga.com/pressreleases/25/10/n48521985/cardinal-health-reports-first-quarter-fiscal-year-2026-results-and-raises-outlook\" rel=\"noreferrer noopener\" target=\"_blank\">increased 37% to $857 million</a>.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Revenue for the Pharmaceutical and Specialty Solutions segment increased 23% to $59.2 billion, driven by growth in brand and specialty pharmaceutical sales from existing and new customers.</p><!--/$--><!--$--><p class=\"block core-block\">First quarter revenue for the Global Medical Products and Distribution segment increased 2% to $3.2 billion, driven by volume growth from existing customers.</p><!--/$--><!--$--><p class=\"block core-block\">Cardinal Health initiated a $375 million accelerated share repurchase program in the first quarter of fiscal year 2026.</p><!--/$--><!--$--><div class=\"sc-SfCGz ciVbir\"></div><!--/$--><!--$--><p class=\"block core-block\">“This outstanding first quarter reflects our focused execution across each of our operating segments and provides a solid foundation as we carry forward. As a result, we are raising our fiscal 2026 outlook,” said CEO <strong>Jason Hollar</strong>.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Outlook</h2><!--/$--><!--$--><p class=\"block core-block\">Cardinal Health raised its outlook for fiscal year 2026 adjusted earnings per share from $9.30-$9.50 to $9.65-$9.85, above the consensus of $9.43.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">The $0.35 increase from the prior range <span style=\"box-sizing:border-box;margin:0px;padding:0px\">reflects the company’s strong first-quarter performance and the expected contributions from the <a href=\"https://www.benzinga.com/m-a/25/08/47058401/cardinal-health-boosts-specialty-presence-with-solaris-health-acquisition-lifts-profit-outlook\" rel=\"noopener\" target=\"_blank\">Solaris Health acquisition</a></span>.</p><!--/$--><!--$--><p class=\"block core-block\">The company expects profit growth in the Pharmaceutical and Specialty Solutions segment of 16%-19%, compared to the prior guidance range of 11%-13%.</p><!--/$--><!--$--><p class=\"block core-block\">The company is also raising its expectations for adjusted free cash flow to $3.0 billion to $3.5 billion, from a prior range of $2.75 billion to $3.25 billion.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Price Action:</strong> CAH stock is trading higher by 16.55% at $191.68 at the last check on Thursday.</p><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/markets/tech/25/10/48520789/tesla-cybercab-to-make-apac-debut-at-chinas-annual-import-expo-in-shanghai-optimus-could-also-be-showcased\" rel=\"noreferrer noopener\" target=\"_blank\">Tesla Cybercab To Make APAC Debut At China’s Annual Import Expo In Shanghai — Optimus Could Also Be Showcased</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Shutterstock</em></p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48535297\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Cardinal-Health.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/25/10/48535297/cardinal-health-rallies-as-strong-start-to-2026-fuels-higher-earnings-guidance",
            "pub_date": "2025-10-31 00:22:52",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6903912decb8a70001459fc6",
            "title": "Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Merck &amp; Co., Inc.</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/MRK\" target=\"_blank\">MRK</a>) stock traded in a volatile session on Thursday following its third-quarter earnings report and updated fiscal 2025 outlook.</p><!--/$--><!--$--><p class=\"block core-block\">The pharma giant reported adjusted earnings per share of $2.58, surpassing <a href=\"https://www.benzinga.com/calendars/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">consensus estimates</a> of $2.35, a jump from $1.57 reported a year ago.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Merck reported sales of $17.28 billion, a 4% increase year-over-year, and exceeded the analysts’ projections of $16.96 billion.</p><!--/$--><!--$--><p class=\"block core-block\"><strong><em>Also Read: <a href=\"https://www.benzinga.com/markets/biotech/25/10/48472199/mercks-new-cancer-therapy-combo-shows-significant-edge-over-rivals-in-renal-cancer\" rel=\"noreferrer noopener\" target=\"_blank\">Merck’s New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer</a></em></strong></p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Segment And Drug Performance</h2><!--/$--><!--$--><p class=\"block core-block\">The pharmaceutical segment recorded $15.61 billion in sales, up 4% year over year, driven by growth in oncology, cardiovascular, and diabetes, partially offset by declines in vaccines, virology, and immunology.</p><!--/$--><!--$--><div class=\"sc-eQzVdq kfhAgV\"></div><!--/$--><!--$--><p class=\"block core-block\">The Animal Health segment’s revenue of $1.62 billion increased 9% year-over-year, primarily driven by the performance of livestock products.</p><!--/$--><!--$--><p class=\"block core-block\">Keytruda, an immunotherapy for cancer, generated $8.14 billion in global sales, representing a 10% year-over-year increase, driven by continued strong demand <a href=\"https://www.benzinga.com/pressreleases/25/10/b48521501/merck-co-inc-rahway-n-j-usa-announces-third-quarter-2025-financial-results\" rel=\"noreferrer noopener\" target=\"_blank\">from metastatic indications</a> worldwide.</p><!--/$--><!--$--><p class=\"block core-block\">GARDASIL and GARDASIL 9, vaccines to prevent HPV-related diseases, generated $1.75 billion in sales, down 24% compared to last year. The company cited lower demand in China.</p><!--/$--><!--$--><p class=\"block core-block\">The diabetes franchise, led by JANUVIA and JANUMET, increased 29% to $624 million.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">Newer products, including Winrevair sales, a therapy for pulmonary arterial hypertension (a rare heart-lung condition), saw sales jump by 141% to 360 million.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Guidance </h2><!--/$--><!--$--><p class=\"block core-block\">Merck raised its fiscal 2025 adjusted earnings guidance <a href=\"https://www.benzinga.com/markets/earnings/25/07/46692220/merck-ceo-sees-minimal-eu-tariffs-impact-warns-of-gardasil-challenges\" rel=\"noreferrer noopener\" target=\"_blank\">from $8.87-$8.97 per share</a> to $8.93-$8.98 compared to the Wall Street estimate of $8.91.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The U.S. drug giant narrowed its fiscal 2025 sales outlook from $64.3 billion to $65.3 billion to $64.5 billion to $65 billion, compared to the consensus estimate of $64.66 billion.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">M&amp;A</h2><!--/$--><!--$--><p class=\"block core-block\">A Merck executive on the company’s conference call stated that the company continues to focus on a potential deal size of $1 billion to $15 billion and is willing to go larger.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>MRK Price Action:</strong> Merck &amp; Co shares were up 0.07% at $86.64 at the time of publication on Thursday, <a href=\"https://www.benzinga.com/pro/\" rel=\"noreferrer noopener\" target=\"_blank\">according to Benzinga Pro data</a>.</p><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><em><a href=\"https://www.benzinga.com/node/48529099\" rel=\"noreferrer noopener\" target=\"_blank\">Mounjaro And Zepbound Power Eli Lilly’s 54% Revenue Jump In Q3, Hikes 2025 Forecast</a></em></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo by Tada Images via Shutterstock</em></p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48535333\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/South-San-Francisco--Ca--Usa---May-1--20.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/25/10/48535333/merck-ready-for-larger-than-15-billion-deals-raises-annual-profit-outlook",
            "pub_date": "2025-10-31 00:24:17",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69038fadecb8a70001459f1a",
            "title": "Nvidia&#39;s $5 Trillion Milestone Turns These AI ETFs Into Hot Trades",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>NVIDIA Corp.</strong>‘s (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/NVDA\" target=\"_blank\">NVDA</a>) market cap just did what no company in history has: crossed the $5 trillion threshold, and ETF investors are racing to catch the wave. </p><!--/$--><!--$--><p class=\"block core-block\">The milestone, fueled by blockbuster AI deals and surging chip demand, has turned <a href=\"https://www.benzinga.com/etfs\" target=\"_blank\">semiconductor ETFs</a> into the hottest trade in town.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Nvidia is up in double digits in the past 5 days.<a href=\"https://www.benzinga.com/quote/nvda\" target=\"_blank\"> Track its prices in real time</a>.</strong></li>\n</ul><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>ETFs Riding The Nvidia Supercycle</strong></h2><!--/$--><!--$--><p class=\"block core-block\">The rally has rippled across funds with heavy Nvidia exposure. The <strong>VanEck Semiconductor ETF</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/SMH\" target=\"_blank\">SMH</a>), which counts Nvidia as its top holding, jumped as investors priced in stronger AI infrastructure demand. The fund ended Wednesday with 1.5% gains after surging even higher earlier in the day. The <strong>Strive U.S. Semiconductor ETF</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/SHOC\" target=\"_blank\">SHOC</a>) and <strong>VanEck Fabless Semiconductor ETF</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/SMHX\" target=\"_blank\">SMHX</a>) also climbed 2% on Wednesday as Nvidia hit the record-breaking milestone, benefiting from the dominance of NVIDIA in the fabless chip segment.</p><!--/$--><!--$--><div class=\"sc-gQfuga iaHpuj\"></div><!--/$--><!--$--><p class=\"block core-block\">Options-based funds, such as the <strong>YieldMax Target 12 Semiconductor Option Income ETF</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/SOXY\" target=\"_blank\">SOXY</a>), have found fresh popularity with yield-starved investors looking for income without missing out on upside. </p><!--/$--><!--$--><p class=\"block core-block\">The ETF momentum is partly a reflection of how Nvidia has become the benchmark for AI growth, a sentiment play that's spreading to the entire semiconductor complex.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>Supercomputers, Self-Driving Cars and A Supply Crunch</strong></h2><!--/$--><!--$--><p class=\"block core-block\">In all, Nvidia’s rally began a week ago with a barrage of announcements at its GTC event in Washington, D.C. The company announced collaborations with the <strong>U.S. Department of Energy </strong>on seven new AI supercomputers, <strong>Uber Technologies Inc</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/UBER\" target=\"_blank\">UBER</a>) on <a href=\"https://www.benzinga.com/markets/tech/25/10/48519612/amid-nvidia-partnership-uber-ceo-dara-khosrowshahi-makes-bold-autonomous-driving-prediction-should-we-allow-humans-to-drive\" target=\"_blank\">100,000 autonomous vehicles through 2027</a>, and <strong>Eli Lilly And Co</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/LLY\" target=\"_blank\">LLY</a>) and <strong>Nokia Oyj </strong>(NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/NOK\" target=\"_blank\">NOK</a>) on biotech and 6G initiatives, respectively.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">At the same time, <strong>SK Hynix</strong>, a critical Nvidia memory supplier, said its entire 2026 output is already sold out, pointing to an extended AI-driven chip boom. That gives the semiconductor trade long-term legs, reinforcing ETF investors’ conviction.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>Trade Truce Tailwinds?</strong></h2><!--/$--><!--$--><p class=\"block core-block\">With a U.S.–China trade thaw post a <a href=\"https://www.benzinga.com/news/politics/25/10/48519309/trump-concludes-amazing-meeting-with-xi-jinping-teases-pretty-soon-trade-deal\" target=\"_blank\">meeting between U.S. President <strong>Donald Trump</strong> and Chinese President <strong>Xi Jinping</strong></a>, Nvidia could regain access to its biggest overseas market. An easing of export restrictions would further strengthen the earnings outlook for the chipmaker and ETFs hitched to its success.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Nvidia’s $5 trillion valuation underlines how strongly the AI story has merged with ETF investing. For as long as GPUs remain at the heart of the global race in AI, semiconductor ETFs might keep rewriting their own record books — one trillion at a time.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48535168\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/markets/tech/25/10/48528320/nvidia-effect-key-suppliers-have-already-sold-out-ai-memory-chips-for-2025\" target=\"_blank\">Nvidia Effect: Key Suppliers Have Already Sold Out AI Memory Chips For 2025</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Mehaniq via Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Kyiv--Ukraine---January-29--2025-Nvidia-.jpeg",
            "link": "https://www.benzinga.com/etfs/sector-etfs/25/10/48535168/nvidias-5-trillion-milestone-turns-these-ai-etfs-into-hot-trades",
            "pub_date": "2025-10-31 00:17:52",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6903903aecb8a70001459f5b",
            "title": "Riot Platforms Stock Dips Ahead Of Q3 Earnings: What Investors Need To Know",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">Shares of <strong>Riot Platforms Inc</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/RIOT\" target=\"_blank\">RIOT</a>) are trading lower Thursday morning as investors anticipate the company’s third-quarter 2025 financial results, due after the market close. The report will provide a crucial update on the company’s <a href=\"https://www.benzinga.com/quote/RIOT/earnings\" target=\"_blank\">performance and outlook</a>.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><em>RIOT is taking a hit from negative sentiment. <a href=\"https://www.benzinga.com/quote/RIOT\" rel=\"noreferrer noopener\" target=\"_blank\">See what the experts say here.</a></em></li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>What To Know:</strong> Wall Street consensus estimates project a net loss of 13 cents per share on quarterly revenue of $170.63 million. Investors will be closely watching for details following recent <a href=\"https://www.benzinga.com/pressreleases/25/10/g48014805/riot-announces-september-2025-production-and-operations-updates\" target=\"_blank\">operational updates</a>. </p><!--/$--><!--$--><p class=\"block core-block\">The company's September production report showed it mined 445 <strong>Bitcoin</strong> (CRYPTO: <a class=\"ticker\" href=\"https://www.benzinga.com/quote/btc/usd\" target=\"_blank\">BTC</a>), a decrease from August. Notably, power credits, a significant revenue stream, fell sharply to $700,000 in September from $15.2 million in the prior month.</p><!--/$--><!--$--><p class=\"block core-block\">Analysts will also seek commentary on the progress of Riot’s high-performance computing colocation strategy, which JPMorgan <a href=\"https://www.benzinga.com/trading-ideas/movers/25/09/47850444/riot-platforms-stock-is-rallying-wednesday-heres-why\" target=\"_blank\">recently highlighted</a> as a key source of potential upside for the bitcoin miner. The company is scheduled to host a conference call to discuss its quarterly results with investors at 4:30 p.m. ET on Thursday.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Benzinga Edge Rankings:</strong> According to <a href=\"http://benzinga.grsm.io/register174\" target=\"_blank\">Benzinga Edge</a> rankings, Riot Platforms boasts an exceptionally strong Momentum score of 96.17.</p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\"><strong>RIOT Price Action:</strong> Riot Platforms shares were down 4.74% at $21.11 at the time of publication on Thursday, <a href=\"https://www.benzinga.com/pro/\" rel=\"noreferrer noopener\" target=\"_blank\">according to Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Read Also: <a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/10/48504348/analyst-says-bitcoin-mining-revenue-and-ebitda-could-rise\" target=\"_blank\">Analyst Says Bitcoin Mining Revenue And EBITDA Could Rise</a></strong></p><!--/$--><!--$--><div class=\"sc-eQzVdq kfhAgV\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">How To Buy RIOT Stock</h2><!--/$--><!--$--><p class=\"block core-block\">Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p><!--/$--><!--$--><p class=\"block core-block\">For example, in Riot Platforms’ case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Image: Shutterstock</em></p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48535229\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Stuttgart--Germany---08-24-2023-Person-H.jpeg",
            "link": "https://www.benzinga.com/trading-ideas/movers/25/10/48535229/riot-platforms-stock-dips-ahead-of-q3-earnings-what-investors-need-to-know",
            "pub_date": "2025-10-31 00:20:15",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69038c26ecb8a70001459c9d",
            "title": "Earnings Outlook For Interface",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">Interface (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/TILE\" target=\"_blank\">TILE</a>) will release its quarterly earnings report on Friday, 2025-10-31. Here's a brief overview for investors ahead of the announcement.</p><!--/$--><!--$--><p class=\"block core-block\">Analysts anticipate Interface to report an <strong>earnings per share</strong> (EPS) of $0.47.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Anticipation surrounds Interface's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p><!--/$--><!--$--><p class=\"block core-block\">New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p><!--/$--><!--$--><h3 class=\"block core-block\">Past Earnings Performance</h3><!--/$--><!--$--><p class=\"block core-block\">The company's EPS beat by $0.13 in the last quarter, leading to a 0.0% drop in the share price on the following day.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a look at Interface's past performance and the resulting price change:</p><!--/$--><!--$--><div class=\"sc-gQfuga iaHpuj\"></div><!--/$--><!--$--><!--/$--><!--$--><div class=\"sc-feVKPA LhjAx core-image flex items-center justify-center\"><span style=\"background:none;border:0;box-sizing:border-box;display:inline-block;height:initial;margin:0;opacity:1;overflow:hidden;padding:0;width:initial;position:relative;max-width:100%\"><span style=\"background:none;border:0;box-sizing:border-box;display:block;height:initial;margin:0;opacity:1;padding:0;width:initial;max-width:100%\"><img alt=\"\" aria-hidden=\"true\" src=\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iNzAwIiBoZWlnaHQ9IjUwMCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIiB2ZXJzaW9uPSIxLjEiLz4=\" style=\"background:none;border:0;display:block;height:initial;margin:0;max-width:100%;opacity:1;padding:0;width:initial\"/></span><img alt=\"\" decoding=\"async\" loading=\"lazy\" src=\"data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/><noscript><img alt=\"\" decoding=\"async\" fetchpriority=\"low\" loading=\"lazy\" sizes=\"(max-width: 800px) 700px, (min-width: 800px) 700px\" src=\"https://www.benzinga.com/files/images/story/2025/1761840166_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=1920\" srcset=\"https://www.benzinga.com/files/images/story/2025/1761840166_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=750 1x, https://www.benzinga.com/files/images/story/2025/1761840166_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=1920 2x\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/></noscript></span></div><!--/$--><!--$--><h3 class=\"block core-block\">Stock Performance</h3><!--/$--><!--$--><p class=\"block core-block\">Shares of Interface were trading at $26.57 as of October 29. Over the last 52-week period, shares are up 15.12%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Analyst Observations about Interface</h3><!--/$--><!--$--><p class=\"block core-block\">For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Interface.</p><!--/$--><!--$--><p class=\"block core-block\">The consensus rating for Interface is Outperform, based on 3 analyst ratings. With an average one-year price target of $32.0, there's a potential 20.44% upside.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Peer Ratings Overview</h3><!--/$--><!--$--><p class=\"block core-block\">The following analysis focuses on the analyst ratings and average 1-year price targets of  and ACCO Brands, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p><!--/$--><!--$--><ul class=\"block core-block\">\n<li>Analysts currently favor an Outperform trajectory for ACCO Brands, with an average 1-year price target of $6.0, suggesting a potential 77.42% downside.</li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Peer Metrics Summary</h3><!--/$--><!--$--><p class=\"block core-block\">Within the peer analysis summary, vital metrics for  and ACCO Brands are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\">Key Takeaway:</p><!--/$--><!--$--><p class=\"block core-block\">Interface outperforms its peers in revenue growth and gross profit, ranking at the top for both metrics. However, it lags behind in return on equity, placing in the middle compared to its peers.</p><!--/$--><!--$--><h3 class=\"block core-block\">Discovering Interface: A Closer Look</h3><!--/$--><!--$--><p class=\"block core-block\">Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.</p><!--/$--><!--$--><h3 class=\"block core-block\">Interface: Financial Performance Dissected</h3><!--/$--><!--$--><p class=\"block core-block\"><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Revenue Growth:</strong> Interface's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately <strong>8.33%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Net Margin:</strong> Interface's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>8.67%,</strong> the company showcases strong profitability and effective cost management.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Equity (ROE):</strong> Interface's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>5.99%,</strong> the company showcases efficient use of equity capital and strong financial health.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Assets (ROA):</strong> Interface's ROA excels beyond industry benchmarks, reaching <strong>2.64%</strong>. This signifies efficient management of assets and strong financial health.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Debt Management:</strong> Interface's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.68</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p><!--/$--><!--$--><p class=\"block core-block\"><a href=\"https://www.benzinga.com/quote/TILE/earnings\" target=\"_blank\"><strong>To track all earnings releases for Interface visit their earnings calendar on our site.</strong></a></p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/earnings/25/10/48534534/earnings-outlook-for-interface",
            "pub_date": "2025-10-31 00:02:50",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}